Company intelligence / Profile preview
Jingxin Pharmaceutical
Xinchang, Zhejiang, Chinajingxinpharm.com ↗
- Ownership
- Private
- Employees
- ~3900
- Development stage
- Other
01
Overview
Jingxin has commercialized Dimdazenil (EVT201) for insomnia in China and has several innovative CNS and cardiovascular drugs in clinical development, including Phase 2 assets for schizophrenia and ulcerative colitis, and a pipeline covering psychiatric, cardiovascular, and digestion indications[4][6].
- Therapeutic areas
- NeurologyPsychiatryCardiovascularGastroenterology
- Modalities
- Small moleculeBiological productsHerbal medicineOligonucleotide
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
EvotecSTADAJiuzhoutong Pharmaceutical GroupBio-Pharm Solutions Co.
Beyond the preview
Go deeper on Jingxin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jingxin Pharmaceutical.